Need professional-grade analysis? Visit stockanalysis.com
$1.20B
N/A
N/A
N/A
Savara Inc (SVRA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $5.78, up 2.48% from the previous close.
Over the past year, SVRA has traded between a low of $1.94 and a high of $6.94. The stock has gained 79.5% over this period. It is currently 16.7% below its 52-week high.
Savara Inc has a market capitalization of $1.20B.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Side-by-side comparison against top Healthcare peers.